Pear Therapeutics, Inc.

Pear Therapeutics, Inc. entered the public markets in December 2021 through its business combination with Thimble Point Acquisition Corp (Nasdaq: THMA), a blank-check vehicle sponsored by Thimble Point LLC that completed its IPO that same year. The combined company operated in the prescription digital therapeutics sector, developing software-based treatments targeting substance use disorder and insomnia. The 8-K filed April 7, 2023 reflects Pear Therapeutics' status amid Chapter 11 bankruptcy proceedings the company initiated earlier in 2023, marking a difficult post-merger trajectory shared by several SPAC-backed digital health names. For complete filing history, sponsor details, and post-merger performance data on THMA and hundreds of other SPAC transactions, sign up for full access at SpacDesk.